VCP
NVAX icon

Verus Capital Partners’s Novavax NVAX Stock Holding History

Verus Capital Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$8K Buy
+602
New +$5.09K ﹤0.01% 1068

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Verus Capital Partners's NVAX Position: Q1 2020 in Review

Verus Capital Partners opened a new position in Novavax (NVAX) in Q1 2020: 602 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #1068 among its holdings.

117 funds tracked by Wall St. Rank hold NVAX as of Q1 2020.

  • Verus Capital Partners held 602 shares of Novavax worth $8K as of Q1 2020.
  • Novavax was a new Verus Capital Partners position in Q1 2020.
  • Novavax made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1068 holding.
  • 117 funds tracked by Wall St. Rank held Novavax as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.